Related Experiment Video
Updated: Jun 10, 2026
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease
A Siderowf1, S X Xie, H Hurtig
1Department of Neurology, 330 South 9th Street, Second Floor, Philadelphia, PA 19107, USA. andrew.siderowf@uphs.upenn.edu
Neurology
|August 20, 2010
Summary
Low levels of cerebrospinal fluid amyloid beta 1-42 (Aβ(1-42)) predict faster cognitive decline in Parkinson disease (PD). This biomarker may help identify patients at risk for progressive cognitive impairment.
Area of Science:
- Neuroscience
- Neurology
- Biomarker Research
Background:
- Cognitive decline is a significant and disabling complication of Parkinson disease (PD).
- Identifying reliable biomarkers for predicting cognitive decline in PD is crucial for clinical management.
- Existing research suggests a potential link between Alzheimer disease pathology and cognitive impairment in PD.
Purpose of the Study:
- To investigate the association between baseline cerebrospinal fluid (CSF) biomarker levels and longitudinal cognitive decline in patients with PD.
- To determine if CSF amyloid beta 1-42 (Aβ(1-42)), p-tau(181p), and total tau levels can predict cognitive decline in PD.
Main Methods:
- Prospective cohort study of 45 PD patients with at least one year of follow-up.
- CSF collection at baseline; cognitive assessment using the Mattis Dementia Rating Scale (DRS-2) at baseline and follow-up.
- Analysis of CSF Aβ(1-42), p-tau(181p), and total tau levels using Luminex xMAP; mixed linear models used for statistical analysis.
Main Results:
- Lower baseline CSF Aβ(1-42) levels were significantly associated with more rapid cognitive decline.
- Patients with CSF Aβ(1-42) ≤192 pg/mL showed an average decline of 5.85 points/year faster on the DRS-2.
- CSF total tau and p-tau(181p) levels did not show a significant association with cognitive decline.
Conclusions:
- Reduced CSF Aβ(1-42) is an independent predictor of cognitive decline in Parkinson disease.
- This finding supports the contribution of Alzheimer disease pathology to cognitive impairment in PD.
- CSF Aβ(1-42) may offer valuable prognostic information for cognitive decline in PD, especially when combined with other risk factors.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.